$SYK

King Debra sold $278K of SYK

King Debra (See Remarks) sold 826 shares of STRYKER CORP (SYK) at $336.30 ($0.28M total) on 2026-08-18.

Original reporting
SEC EDGAR · King Debra
Published Aug 18, 2026, 8:34 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 18, 2026, 10:18 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$SYK
Neutral
medium confidence
Mentioned
$SYK
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$SYKNeutralLow
01

Why it matters

The only new fact is the reported sale details (shares, price, total value, and post-transaction holdings).

02

Market read

Traders may briefly reassess sentiment around SYK due to an insider sale, but there is no accompanying fundamental catalyst in the text.

03

What to watch

Insider sales can be driven by diversification, taxes, or pre-existing personal liquidity needs; the filing lacks any stated reason or linkage to company fundamentals.

Relevance 4/10Novelty 3/10Timing: filed 2026-08-18, transaction dated 2026-08-18

Background

The article is an SEC Form 4 insider transaction disclosure for Stryker (SYK).

Company-level read

Ticker impact

$SYKNeutralMedium confidence
Context

Stryker Form 4 shows officer King Debra sold 826 shares on 2026-08-18 at $336.3040, totaling $277,787.10.

Expected impact

Likely minimal near-term impact; any effect would be sentiment-driven and typically fades unless accompanied by other disclosures.

Evidence & confidence

The filing is a Form 4 insider transaction. The article provides transaction size, price, and post-sale holdings, but no new company-specific operational or financial information.

Market effects

No clear sector read-through from a single insider sale at this scale.

None.

None.

Counterpoint

Absence of a disclosed 10b5-1 plan can be interpreted by some traders as less “scheduled,” potentially adding short-term bearish sentiment.

Key entities

  • STRYKER CORP

    Company whose insider transaction was disclosed via Form 4.

  • King Debra

    Officer who sold 826 shares on 2026-08-18.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$GDMed

General Dynamics gets $136M to upgrade Stryker power system

General Dynamics Land Systems received a $135.9M contract modification from the U.S. Army to upgrade Stryker armored vehicles' power systems, increasing the total contract value to $162.4M. The contract, running until 2030, covers retrofit kits for existing Strykers, though specifics on quantities and timelines were not disclosed. General Dynamics was the sole bidder. This follows another $54.3M contract for Stryker maintenance and sustainment through 2031.

$SYKHighAI 8/10

Stryker Closes ZuriMED Acquisition Adding Rotator Cuff Technology

Stryker completed its acquisition of privately held ZuriMED Technologies AG, adding the FiberLocker System to its Sports Medicine portfolio. The system, designed to strengthen rotator cuff repairs, received FDA clearance in 2024. Stryker aims to expand its shoulder care capabilities with this acquisition, though financial terms were not disclosed.

$SYKHighAI 9/10

Nelson Advisors: Stryker’s investment in CMR Surgical marks the beginning of an era of multi platform competition in soft tissue robotic surgery

Stryker invested $400M in CMR Surgical, gaining U.S. distribution rights and an option to acquire the company. The deal aims to compete in soft-tissue robotic surgery, a market previously dominated by Intuitive Surgical. CMR's Versius platform offers modular, portable design and advanced imaging. Stryker's Spencer Stiles will become CEO in 2027, overseeing the partnership.